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ABSTRACT
To determine the clinical profiles, management and outcome of myasthenic crisis (MC) in patients presenting to a 
tertiary care hospital in Karachi, Pakistan. This was a retrospective study of forty patients with Myasthenic crisis(MC) 
admitted at the Aga Khan University Hospital, Karachi  between 1999 and 2014.Demographics, clinical presentation, 
hospital course, management and outcomes were reviewed. Ventilatory support for respiratory muscle or bulbar 
weakness was taken as crisis identification at arrival. Out of the total 40 patients with MC; generalized onset was seen 
in 28 (70%) and isolated bulbar symptoms in 12 (30%) patients. Fifteen patients (37.5%) had MC as a first 
presentation. In a third world country with insufficient resources and limited access to specialist care, early recognition 
of MC by general practitioners is important. Patient education about avoidance of possible precipitating factors and 
recognition of early symptoms of MC is essential.
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INTRODUCTION
Myasthenic crisis (MC) is defined by the presence of 
respiratory failure and the need for invasive or 
noninvasive mechanical ventilation.1 The most severe 
level of weakness and high mortality occurs during the 
first 1 to 2 years of disease onset, after which many 
patients experience improvement.2 Administration of 
non-invasive positive pressure ventilation (NIPPV) has 
enabled us to treat some MC patients in the general 
ward without intubation6 however, other serious MCs 
still require intensive care with intubation.7 Plasma 
exchange (PE) and intravenous immunoglobulin (IVIG) 
are used to treat myasthenia gravis (MG) exacerbations 
and crises.10  In-hospital mortality of MG is low. Hospital 
utilization of IVIG has significantly increased compared 
to PE and thymectomy.11
METHOD
Sixty one adult patients with MC or suspected MC 
presenting to the Aga Khan University Hospital, 
Karachi, Pakistan between 1999 and 2014 were 
studied retrospectively. The age range was between 18 
to 80 years. Need for ventilatory support due to 
respiratory muscle or bulbar weakness was taken as 
crisis identification. Twenty one patients were excluded 
from this study due to various reasons including 
misdiagnosis of crisis, diagnosis of some other 
neuromuscular (NM) disorders  or inadequate data. 
Ultimately data pertaining to demographics, clinical 
presentation, hospital course, management and 
outcomes of 40 cases with MC were reviewed. The 
Statistical Package for Social Sciences (SPSS V.19) 
was used for statistical analysis. Results are presented 
as frequency and percentages for qualitative variables 
and mean, and SD for quantitative variables. Analysis 
of variance was used to assess differences between 
sexes and age groups. This study was approved by the 
ethics review committee of the Aga Khan University 
Hospital.
RESULTS
Median age at presentation of MC was 50 years with 
24 (60%) males and 16(40%) females .Ten patients 
(25%) were admitted through outpatient clinics and 
30(75%) were admitted through the emergency 
department. Out of a total of 40 patients with MC: 
28(70%) had a generalized onset and 12 (30%) had 
O R I G I N A L  A R T I C L E
isolated bulbar symptoms. Details of basic 
investigations done for the diagnosis and work-up of 
myasthenia gravis are listed in Table 1.
The most common triggering factor seen was infection 
in 19 (47.5%) including respiratory infections and 
gastroenterits ,while non-compliance to medications 
by known myasthenic patients was noted in  6 (15%). 
3(7.5%) had a recent surgery as an inciting factor and 
4(10%)  patients either were on inadequate dosing or 
had poor response to medications. The mean duration 
of diagnosis of MG prior to presenting with crisis was 
33.9 days. It was the first presentation of MG in 15 
(37.5%) patients.
Thymectomy had been done prior to presentation in 9 
(22.5%) with MC.
16 (40%) were admitted to the ICU requiring ventilator 
support, 15 (37.5%) were treated with non-invasive 
ventilation in the special care units and 9 (22.5%) were 
managed on the general neurology floor.21 (53.8%) 
patients had a delay in start of treatment either due to 
delay in recognition that the patient was in crisis, due 
to patient reluctance for treatment of MG or 
management at non specialist hospitals.
Treatment options of plasmapheresis and IVIG were 
offered to all patients. However choice by the patient/ 
family was made according to financial constraints or 
personal preference. Plasmapharesis was done in 18 
(45%), IVIG was given to 11/40 (27.5%) and pulse 
steroids to 8 (20%) patients for MC. One elderly patient 
refused treatment and 2 patients were transferred to 
other facilities due to unavailability of an ICU bed.  13 
(32%) patients were on immunosuppressants at 
presentation. The mean duration of hospitalization was 
12.7 days. Some patients had other comorbidities like 
diabetes in 11 (27.5%) and hypertension in 7(17.5%) 
which may have increased complications and 
prolonged hospital stay, however a causal relationship 
could not be established.
All 38 treated (95%) patients were discharged home. 
At 3 months follow up post discharge 29 (72.5%) were 
stable on medications while 11 (27.5%) were lost to 
follow up specially those who had come in from distant 
areas of Pakistan or from Afghanistan.
DISCUSSION
All our patients were offered and treated with standard 
available therapy including PE, IVIG and intravenous 
pulse steroid therapy.
A retrospective review of hospital records of 53 patients 
admitted for 73 episodes of MC at the 
Columbia-Presbyterian Medical Center over a period of 
12 years, from 1983 to 1994 showed a median age at 
onset of first MC to be 55 years (range: 20 to 82), with 
the ratio of women to men of 2:1.4 In our study, the 
median age of presentation with MC was similar at 50 
years, however there was a male pre-dominance with 
sixty percent male patients. The reason for this is 
unclear, since, similar to other populations; the 
prevalence of MG is higher in women in Pakistan.12 
Perhaps access to tertiary health care for women in 
critical condition is an issue. 
In a large retrospective analysis from a NM diseases 
registry in Spain that included 648 patients with MG, 
out of 62 patients who presented with a life threatening 
event like dysphagia or respiratory weakness, it was the 
first manifestation of MG for 50%. 7 In comparison, in 
our very small sample, MC was the first presentation of 
MG for 15/40 (37.5%) patients.  More than 50%  of 
the patients had aggravated symptoms of MC due to 
late diagnosis. These are substantially high numbers 
and underline the importance of creating awareness 
amongst the general neurologists in the community of 
identifying MC in the absence of a previous diagnosis of 
MG, to ensure early access and referral to appropriate 
level of health care. 
The most common known precipitant is infection in 
approximately 38% of MC patients4   and this was 
similar in our study showing infection as the leading 
cause in 47.5% patients while 6/40 (15%) were 
non-compliant to medications. This highlights the 
importance of extensive counseling for all myasthenic 
patients at initial diagnosis, about the nature of 
disease, need for prolonged treatment, precipitating 
factors and identifying early signs of crisis. These 
simple measures can prevent a crisis in the first place 
and/or prevent morbidity, mortality and the cost that 
goes with its management. In a large study done in Iran 
over 17 years it was found that 18.2% of 
thymectomized patients (20 of 110) and 38.5% of 
non-thymectomized patients (42 of 109) had MC. This 
was significant (P = 0.001; odds ratio = 2.8 with 95% 
CI of 1.5 to 5.2).Likewise most of our patients with MC 
31(77.5 %) had not undergone a thymectomy. Ocular 
myasthenia has less clinical worsening episodes and a 
higher chance of complete stable remission. 
Generalized disease has less chance of a drug free 
remission. The risks of episodes of worsening persist at 
a steady rate over a period of time, being maximum in 
the first year. Risk of exacerbations is unpredictable and 
can occur after prolonged clinical quiescence, often 
related to reduction of immunosuppression8 and 13 
(32.5%) of our patients were already on some 
immunosuppressant when presented with MC.
Due to the retrospective nature of our study, we were 
unable to establish clinically relevant associations 
especially between MC and response to different 
treatment modalities. Treatment between PE and IVIG 
was based on affordability of the patients rather than 
being truly randomized. Clinical data was deficient 
which resulted in excluding otherwise eligible patients. 
CONCLUSION
Basic education regarding MC to general practitioners 
in Pakistan is of profound importance as they are the 
ones who treat majority of such patients and 
precautions to diagnosed patients with MG regarding 
avoidance of possible precipitants may lead to early 
diagnosis and more efficient clinical care.
MC in this advanced era of medicine is still a significant 
cause of prolonged hospitalization and increased 
mortality and morbidity especially with limited 
resources in a third world country like Pakistan. 
Respiratory support with IVIG, plasmapheresis or 
intravenous pulse steroids remain the mainstays of 
treatments without any significant difference in 
outcome with either use. Patient education about 
avoidance of possible precipitating factors and 
recognizing early symptoms of MC should be part of 
standard care. The data available on myasthenic crisis 
in our region of Southeast Asia is scarce and this needs 
to be looked into to improve the living standards of 
known MG patients and those who develop MC.
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INTRODUCTION
Myasthenic crisis (MC) is defined by the presence of 
respiratory failure and the need for invasive or 
noninvasive mechanical ventilation.1 The most severe 
level of weakness and high mortality occurs during the 
first 1 to 2 years of disease onset, after which many 
patients experience improvement.2 Administration of 
non-invasive positive pressure ventilation (NIPPV) has 
enabled us to treat some MC patients in the general 
ward without intubation6 however, other serious MCs 
still require intensive care with intubation.7 Plasma 
exchange (PE) and intravenous immunoglobulin (IVIG) 
are used to treat myasthenia gravis (MG) exacerbations 
and crises.10  In-hospital mortality of MG is low. Hospital 
utilization of IVIG has significantly increased compared 
to PE and thymectomy.11
METHOD
Sixty one adult patients with MC or suspected MC 
presenting to the Aga Khan University Hospital, 
Karachi, Pakistan between 1999 and 2014 were 
studied retrospectively. The age range was between 18 
to 80 years. Need for ventilatory support due to 
respiratory muscle or bulbar weakness was taken as 
crisis identification. Twenty one patients were excluded 
from this study due to various reasons including 
misdiagnosis of crisis, diagnosis of some other 
neuromuscular (NM) disorders  or inadequate data. 
Ultimately data pertaining to demographics, clinical 
presentation, hospital course, management and 
outcomes of 40 cases with MC were reviewed. The 
Statistical Package for Social Sciences (SPSS V.19) 
was used for statistical analysis. Results are presented 
as frequency and percentages for qualitative variables 
and mean, and SD for quantitative variables. Analysis 
of variance was used to assess differences between 
sexes and age groups. This study was approved by the 
ethics review committee of the Aga Khan University 
Hospital.
RESULTS
Median age at presentation of MC was 50 years with 
24 (60%) males and 16(40%) females .Ten patients 
(25%) were admitted through outpatient clinics and 
30(75%) were admitted through the emergency 
department. Out of a total of 40 patients with MC: 
28(70%) had a generalized onset and 12 (30%) had 
isolated bulbar symptoms. Details of basic 
investigations done for the diagnosis and work-up of 
myasthenia gravis are listed in Table 1.
The most common triggering factor seen was infection 
in 19 (47.5%) including respiratory infections and 
gastroenterits ,while non-compliance to medications 
by known myasthenic patients was noted in  6 (15%). 
3(7.5%) had a recent surgery as an inciting factor and 
4(10%)  patients either were on inadequate dosing or 
had poor response to medications. The mean duration 
of diagnosis of MG prior to presenting with crisis was 
33.9 days. It was the first presentation of MG in 15 
(37.5%) patients.
Thymectomy had been done prior to presentation in 9 
(22.5%) with MC.
16 (40%) were admitted to the ICU requiring ventilator 
support, 15 (37.5%) were treated with non-invasive 
ventilation in the special care units and 9 (22.5%) were 
managed on the general neurology floor.21 (53.8%) 
patients had a delay in start of treatment either due to 
delay in recognition that the patient was in crisis, due 
to patient reluctance for treatment of MG or 
management at non specialist hospitals.
Treatment options of plasmapheresis and IVIG were 
offered to all patients. However choice by the patient/ 
family was made according to financial constraints or 
personal preference. Plasmapharesis was done in 18 
(45%), IVIG was given to 11/40 (27.5%) and pulse 
steroids to 8 (20%) patients for MC. One elderly patient 
refused treatment and 2 patients were transferred to 
other facilities due to unavailability of an ICU bed.  13 
(32%) patients were on immunosuppressants at 
presentation. The mean duration of hospitalization was 
12.7 days. Some patients had other comorbidities like 
diabetes in 11 (27.5%) and hypertension in 7(17.5%) 
which may have increased complications and 
prolonged hospital stay, however a causal relationship 
could not be established.
All 38 treated (95%) patients were discharged home. 
At 3 months follow up post discharge 29 (72.5%) were 
stable on medications while 11 (27.5%) were lost to 
follow up specially those who had come in from distant 
areas of Pakistan or from Afghanistan.
DISCUSSION
All our patients were offered and treated with standard 
available therapy including PE, IVIG and intravenous 
pulse steroid therapy.
A retrospective review of hospital records of 53 patients 
admitted for 73 episodes of MC at the 
Columbia-Presbyterian Medical Center over a period of 
12 years, from 1983 to 1994 showed a median age at 
onset of first MC to be 55 years (range: 20 to 82), with 
the ratio of women to men of 2:1.4 In our study, the 
median age of presentation with MC was similar at 50 
years, however there was a male pre-dominance with 
sixty percent male patients. The reason for this is 
unclear, since, similar to other populations; the 
prevalence of MG is higher in women in Pakistan.12 
Perhaps access to tertiary health care for women in 
critical condition is an issue. 
In a large retrospective analysis from a NM diseases 
registry in Spain that included 648 patients with MG, 
out of 62 patients who presented with a life threatening 
event like dysphagia or respiratory weakness, it was the 
first manifestation of MG for 50%. 7 In comparison, in 
our very small sample, MC was the first presentation of 
MG for 15/40 (37.5%) patients.  More than 50%  of 
the patients had aggravated symptoms of MC due to 
late diagnosis. These are substantially high numbers 
and underline the importance of creating awareness 
amongst the general neurologists in the community of 
identifying MC in the absence of a previous diagnosis of 
MG, to ensure early access and referral to appropriate 
level of health care. 
The most common known precipitant is infection in 
approximately 38% of MC patients4   and this was 
similar in our study showing infection as the leading 
cause in 47.5% patients while 6/40 (15%) were 
non-compliant to medications. This highlights the 
importance of extensive counseling for all myasthenic 
patients at initial diagnosis, about the nature of 
disease, need for prolonged treatment, precipitating 
factors and identifying early signs of crisis. These 
simple measures can prevent a crisis in the first place 
and/or prevent morbidity, mortality and the cost that 
goes with its management. In a large study done in Iran 
over 17 years it was found that 18.2% of 
thymectomized patients (20 of 110) and 38.5% of 
non-thymectomized patients (42 of 109) had MC. This 
was significant (P = 0.001; odds ratio = 2.8 with 95% 
CI of 1.5 to 5.2).Likewise most of our patients with MC 
31(77.5 %) had not undergone a thymectomy. Ocular 
myasthenia has less clinical worsening episodes and a 
higher chance of complete stable remission. 
Generalized disease has less chance of a drug free 
remission. The risks of episodes of worsening persist at 
a steady rate over a period of time, being maximum in 
the first year. Risk of exacerbations is unpredictable and 
can occur after prolonged clinical quiescence, often 
related to reduction of immunosuppression8 and 13 
(32.5%) of our patients were already on some 
immunosuppressant when presented with MC.
Due to the retrospective nature of our study, we were 
unable to establish clinically relevant associations 
especially between MC and response to different 
treatment modalities. Treatment between PE and IVIG 
was based on affordability of the patients rather than 
being truly randomized. Clinical data was deficient 
which resulted in excluding otherwise eligible patients. 
CONCLUSION
Basic education regarding MC to general practitioners 
in Pakistan is of profound importance as they are the 
ones who treat majority of such patients and 
precautions to diagnosed patients with MG regarding 
avoidance of possible precipitants may lead to early 
diagnosis and more efficient clinical care.
MC in this advanced era of medicine is still a significant 
cause of prolonged hospitalization and increased 
mortality and morbidity especially with limited 
resources in a third world country like Pakistan. 
Respiratory support with IVIG, plasmapheresis or 
intravenous pulse steroids remain the mainstays of 
treatments without any significant difference in 
outcome with either use. Patient education about 
avoidance of possible precipitating factors and 
recognizing early symptoms of MC should be part of 
standard care. The data available on myasthenic crisis 
in our region of Southeast Asia is scarce and this needs 
to be looked into to improve the living standards of 
known MG patients and those who develop MC.
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INTRODUCTION
Myasthenic crisis (MC) is defined by the presence of 
respiratory failure and the need for invasive or 
noninvasive mechanical ventilation.1 The most severe 
level of weakness and high mortality occurs during the 
first 1 to 2 years of disease onset, after which many 
patients experience improvement.2 Administration of 
non-invasive positive pressure ventilation (NIPPV) has 
enabled us to treat some MC patients in the general 
ward without intubation6 however, other serious MCs 
still require intensive care with intubation.7 Plasma 
exchange (PE) and intravenous immunoglobulin (IVIG) 
are used to treat myasthenia gravis (MG) exacerbations 
and crises.10  In-hospital mortality of MG is low. Hospital 
utilization of IVIG has significantly increased compared 
to PE and thymectomy.11
METHOD
Sixty one adult patients with MC or suspected MC 
presenting to the Aga Khan University Hospital, 
Karachi, Pakistan between 1999 and 2014 were 
studied retrospectively. The age range was between 18 
to 80 years. Need for ventilatory support due to 
respiratory muscle or bulbar weakness was taken as 
crisis identification. Twenty one patients were excluded 
from this study due to various reasons including 
misdiagnosis of crisis, diagnosis of some other 
neuromuscular (NM) disorders  or inadequate data. 
Ultimately data pertaining to demographics, clinical 
presentation, hospital course, management and 
outcomes of 40 cases with MC were reviewed. The 
Statistical Package for Social Sciences (SPSS V.19) 
was used for statistical analysis. Results are presented 
as frequency and percentages for qualitative variables 
and mean, and SD for quantitative variables. Analysis 
of variance was used to assess differences between 
sexes and age groups. This study was approved by the 
ethics review committee of the Aga Khan University 
Hospital.
RESULTS
Median age at presentation of MC was 50 years with 
24 (60%) males and 16(40%) females .Ten patients 
(25%) were admitted through outpatient clinics and 
30(75%) were admitted through the emergency 
department. Out of a total of 40 patients with MC: 
28(70%) had a generalized onset and 12 (30%) had 
isolated bulbar symptoms. Details of basic 
investigations done for the diagnosis and work-up of 
myasthenia gravis are listed in Table 1.
The most common triggering factor seen was infection 
in 19 (47.5%) including respiratory infections and 
gastroenterits ,while non-compliance to medications 
by known myasthenic patients was noted in  6 (15%). 
3(7.5%) had a recent surgery as an inciting factor and 
4(10%)  patients either were on inadequate dosing or 
had poor response to medications. The mean duration 
of diagnosis of MG prior to presenting with crisis was 
33.9 days. It was the first presentation of MG in 15 
(37.5%) patients.
Thymectomy had been done prior to presentation in 9 
(22.5%) with MC.
16 (40%) were admitted to the ICU requiring ventilator 
support, 15 (37.5%) were treated with non-invasive 
ventilation in the special care units and 9 (22.5%) were 
managed on the general neurology floor.21 (53.8%) 
patients had a delay in start of treatment either due to 
delay in recognition that the patient was in crisis, due 
to patient reluctance for treatment of MG or 
management at non specialist hospitals.
Treatment options of plasmapheresis and IVIG were 
offered to all patients. However choice by the patient/ 
family was made according to financial constraints or 
personal preference. Plasmapharesis was done in 18 
(45%), IVIG was given to 11/40 (27.5%) and pulse 
steroids to 8 (20%) patients for MC. One elderly patient 
refused treatment and 2 patients were transferred to 
other facilities due to unavailability of an ICU bed.  13 
(32%) patients were on immunosuppressants at 
presentation. The mean duration of hospitalization was 
12.7 days. Some patients had other comorbidities like 
diabetes in 11 (27.5%) and hypertension in 7(17.5%) 
which may have increased complications and 
prolonged hospital stay, however a causal relationship 
could not be established.
All 38 treated (95%) patients were discharged home. 
At 3 months follow up post discharge 29 (72.5%) were 
stable on medications while 11 (27.5%) were lost to 
follow up specially those who had come in from distant 
areas of Pakistan or from Afghanistan.
DISCUSSION
All our patients were offered and treated with standard 
available therapy including PE, IVIG and intravenous 
pulse steroid therapy.
A retrospective review of hospital records of 53 patients 
admitted for 73 episodes of MC at the 
Columbia-Presbyterian Medical Center over a period of 
12 years, from 1983 to 1994 showed a median age at 
onset of first MC to be 55 years (range: 20 to 82), with 
the ratio of women to men of 2:1.4 In our study, the 
median age of presentation with MC was similar at 50 
years, however there was a male pre-dominance with 
sixty percent male patients. The reason for this is 
unclear, since, similar to other populations; the 
prevalence of MG is higher in women in Pakistan.12 
Perhaps access to tertiary health care for women in 
critical condition is an issue. 
In a large retrospective analysis from a NM diseases 
registry in Spain that included 648 patients with MG, 
out of 62 patients who presented with a life threatening 
event like dysphagia or respiratory weakness, it was the 
first manifestation of MG for 50%. 7 In comparison, in 
our very small sample, MC was the first presentation of 
MG for 15/40 (37.5%) patients.  More than 50%  of 
the patients had aggravated symptoms of MC due to 
late diagnosis. These are substantially high numbers 
and underline the importance of creating awareness 
amongst the general neurologists in the community of 
identifying MC in the absence of a previous diagnosis of 
MG, to ensure early access and referral to appropriate 
level of health care. 
The most common known precipitant is infection in 
approximately 38% of MC patients4   and this was 
similar in our study showing infection as the leading 
cause in 47.5% patients while 6/40 (15%) were 
non-compliant to medications. This highlights the 
importance of extensive counseling for all myasthenic 
patients at initial diagnosis, about the nature of 
disease, need for prolonged treatment, precipitating 
factors and identifying early signs of crisis. These 
simple measures can prevent a crisis in the first place 
and/or prevent morbidity, mortality and the cost that 
goes with its management. In a large study done in Iran 
over 17 years it was found that 18.2% of 
thymectomized patients (20 of 110) and 38.5% of 
non-thymectomized patients (42 of 109) had MC. This 
was significant (P = 0.001; odds ratio = 2.8 with 95% 
CI of 1.5 to 5.2).Likewise most of our patients with MC 
31(77.5 %) had not undergone a thymectomy. Ocular 
myasthenia has less clinical worsening episodes and a 
higher chance of complete stable remission. 
Generalized disease has less chance of a drug free 
remission. The risks of episodes of worsening persist at 
a steady rate over a period of time, being maximum in 
the first year. Risk of exacerbations is unpredictable and 
can occur after prolonged clinical quiescence, often 
related to reduction of immunosuppression8 and 13 
(32.5%) of our patients were already on some 
immunosuppressant when presented with MC.
Due to the retrospective nature of our study, we were 
unable to establish clinically relevant associations 
especially between MC and response to different 
treatment modalities. Treatment between PE and IVIG 
was based on affordability of the patients rather than 
being truly randomized. Clinical data was deficient 
which resulted in excluding otherwise eligible patients. 
CONCLUSION
Basic education regarding MC to general practitioners 
in Pakistan is of profound importance as they are the 
ones who treat majority of such patients and 
precautions to diagnosed patients with MG regarding 
avoidance of possible precipitants may lead to early 
diagnosis and more efficient clinical care.
MC in this advanced era of medicine is still a significant 
cause of prolonged hospitalization and increased 
mortality and morbidity especially with limited 
resources in a third world country like Pakistan. 
Respiratory support with IVIG, plasmapheresis or 
intravenous pulse steroids remain the mainstays of 
treatments without any significant difference in 
outcome with either use. Patient education about 
avoidance of possible precipitating factors and 
recognizing early symptoms of MC should be part of 
standard care. The data available on myasthenic crisis 
in our region of Southeast Asia is scarce and this needs 
to be looked into to improve the living standards of 
known MG patients and those who develop MC.
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ABBREVIATIONS
MC:  Myasthenic Crisis
MG: Myasthenia Gravis
RNS: Repetitive Nerve Stimulation
AChRAb: Acetyl Choline Receptor Antibody
PE: Plasma Exchange
IVIG: Intravenous Immunoglobulin
BiPAP: Bilevel positive airway pressure
NM:Neuromuscular
Table 1: Results for investigations done for the 
evaluation of Myasthenia Gravis (N=40)
RNS: Repetitive nerve stimulation; AChRAb: Acetyl 
Choline Receptor Antibody
CK: Creatinine phosphokinase
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INTRODUCTION
Myasthenic crisis (MC) is defined by the presence of 
respiratory failure and the need for invasive or 
noninvasive mechanical ventilation.1 The most severe 
level of weakness and high mortality occurs during the 
first 1 to 2 years of disease onset, after which many 
patients experience improvement.2 Administration of 
non-invasive positive pressure ventilation (NIPPV) has 
enabled us to treat some MC patients in the general 
ward without intubation6 however, other serious MCs 
still require intensive care with intubation.7 Plasma 
exchange (PE) and intravenous immunoglobulin (IVIG) 
are used to treat myasthenia gravis (MG) exacerbations 
and crises.10  In-hospital mortality of MG is low. Hospital 
utilization of IVIG has significantly increased compared 
to PE and thymectomy.11
METHOD
Sixty one adult patients with MC or suspected MC 
presenting to the Aga Khan University Hospital, 
Karachi, Pakistan between 1999 and 2014 were 
studied retrospectively. The age range was between 18 
to 80 years. Need for ventilatory support due to 
respiratory muscle or bulbar weakness was taken as 
crisis identification. Twenty one patients were excluded 
from this study due to various reasons including 
misdiagnosis of crisis, diagnosis of some other 
neuromuscular (NM) disorders  or inadequate data. 
Ultimately data pertaining to demographics, clinical 
presentation, hospital course, management and 
outcomes of 40 cases with MC were reviewed. The 
Statistical Package for Social Sciences (SPSS V.19) 
was used for statistical analysis. Results are presented 
as frequency and percentages for qualitative variables 
and mean, and SD for quantitative variables. Analysis 
of variance was used to assess differences between 
sexes and age groups. This study was approved by the 
ethics review committee of the Aga Khan University 
Hospital.
RESULTS
Median age at presentation of MC was 50 years with 
24 (60%) males and 16(40%) females .Ten patients 
(25%) were admitted through outpatient clinics and 
30(75%) were admitted through the emergency 
department. Out of a total of 40 patients with MC: 
28(70%) had a generalized onset and 12 (30%) had 
isolated bulbar symptoms. Details of basic 
investigations done for the diagnosis and work-up of 
myasthenia gravis are listed in Table 1.
The most common triggering factor seen was infection 
in 19 (47.5%) including respiratory infections and 
gastroenterits ,while non-compliance to medications 
by known myasthenic patients was noted in  6 (15%). 
3(7.5%) had a recent surgery as an inciting factor and 
4(10%)  patients either were on inadequate dosing or 
had poor response to medications. The mean duration 
of diagnosis of MG prior to presenting with crisis was 
33.9 days. It was the first presentation of MG in 15 
(37.5%) patients.
Thymectomy had been done prior to presentation in 9 
(22.5%) with MC.
16 (40%) were admitted to the ICU requiring ventilator 
support, 15 (37.5%) were treated with non-invasive 
ventilation in the special care units and 9 (22.5%) were 
managed on the general neurology floor.21 (53.8%) 
patients had a delay in start of treatment either due to 
delay in recognition that the patient was in crisis, due 
to patient reluctance for treatment of MG or 
management at non specialist hospitals.
Treatment options of plasmapheresis and IVIG were 
offered to all patients. However choice by the patient/ 
family was made according to financial constraints or 
personal preference. Plasmapharesis was done in 18 
(45%), IVIG was given to 11/40 (27.5%) and pulse 
steroids to 8 (20%) patients for MC. One elderly patient 
refused treatment and 2 patients were transferred to 
other facilities due to unavailability of an ICU bed.  13 
(32%) patients were on immunosuppressants at 
presentation. The mean duration of hospitalization was 
12.7 days. Some patients had other comorbidities like 
diabetes in 11 (27.5%) and hypertension in 7(17.5%) 
which may have increased complications and 
prolonged hospital stay, however a causal relationship 
could not be established.
All 38 treated (95%) patients were discharged home. 
At 3 months follow up post discharge 29 (72.5%) were 
stable on medications while 11 (27.5%) were lost to 
follow up specially those who had come in from distant 
areas of Pakistan or from Afghanistan.
DISCUSSION
All our patients were offered and treated with standard 
available therapy including PE, IVIG and intravenous 
pulse steroid therapy.
A retrospective review of hospital records of 53 patients 
admitted for 73 episodes of MC at the 
Columbia-Presbyterian Medical Center over a period of 
12 years, from 1983 to 1994 showed a median age at 
onset of first MC to be 55 years (range: 20 to 82), with 
the ratio of women to men of 2:1.4 In our study, the 
median age of presentation with MC was similar at 50 
years, however there was a male pre-dominance with 
sixty percent male patients. The reason for this is 
unclear, since, similar to other populations; the 
prevalence of MG is higher in women in Pakistan.12 
Perhaps access to tertiary health care for women in 
critical condition is an issue. 
In a large retrospective analysis from a NM diseases 
registry in Spain that included 648 patients with MG, 
out of 62 patients who presented with a life threatening 
event like dysphagia or respiratory weakness, it was the 
first manifestation of MG for 50%. 7 In comparison, in 
our very small sample, MC was the first presentation of 
MG for 15/40 (37.5%) patients.  More than 50%  of 
the patients had aggravated symptoms of MC due to 
late diagnosis. These are substantially high numbers 
and underline the importance of creating awareness 
amongst the general neurologists in the community of 
identifying MC in the absence of a previous diagnosis of 
MG, to ensure early access and referral to appropriate 
level of health care. 
The most common known precipitant is infection in 
approximately 38% of MC patients4   and this was 
similar in our study showing infection as the leading 
cause in 47.5% patients while 6/40 (15%) were 
non-compliant to medications. This highlights the 
importance of extensive counseling for all myasthenic 
patients at initial diagnosis, about the nature of 
disease, need for prolonged treatment, precipitating 
factors and identifying early signs of crisis. These 
simple measures can prevent a crisis in the first place 
and/or prevent morbidity, mortality and the cost that 
goes with its management. In a large study done in Iran 
over 17 years it was found that 18.2% of 
thymectomized patients (20 of 110) and 38.5% of 
non-thymectomized patients (42 of 109) had MC. This 
was significant (P = 0.001; odds ratio = 2.8 with 95% 
CI of 1.5 to 5.2).Likewise most of our patients with MC 
31(77.5 %) had not undergone a thymectomy. Ocular 
myasthenia has less clinical worsening episodes and a 
higher chance of complete stable remission. 
Generalized disease has less chance of a drug free 
remission. The risks of episodes of worsening persist at 
a steady rate over a period of time, being maximum in 
the first year. Risk of exacerbations is unpredictable and 
can occur after prolonged clinical quiescence, often 
related to reduction of immunosuppression8 and 13 
(32.5%) of our patients were already on some 
immunosuppressant when presented with MC.
Due to the retrospective nature of our study, we were 
unable to establish clinically relevant associations 
especially between MC and response to different 
treatment modalities. Treatment between PE and IVIG 
was based on affordability of the patients rather than 
being truly randomized. Clinical data was deficient 
which resulted in excluding otherwise eligible patients. 
CONCLUSION
Basic education regarding MC to general practitioners 
in Pakistan is of profound importance as they are the 
ones who treat majority of such patients and 
precautions to diagnosed patients with MG regarding 
avoidance of possible precipitants may lead to early 
diagnosis and more efficient clinical care.
MC in this advanced era of medicine is still a significant 
cause of prolonged hospitalization and increased 
mortality and morbidity especially with limited 
resources in a third world country like Pakistan. 
Respiratory support with IVIG, plasmapheresis or 
intravenous pulse steroids remain the mainstays of 
treatments without any significant difference in 
outcome with either use. Patient education about 
avoidance of possible precipitating factors and 
recognizing early symptoms of MC should be part of 
standard care. The data available on myasthenic crisis 
in our region of Southeast Asia is scarce and this needs 
to be looked into to improve the living standards of 
known MG patients and those who develop MC.
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